drugset / Trial / NCT00425256
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Phase 2
Completed
Palatin Technologies, Inc
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupDouble-blind
Summary
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Timeline
- Start
- 2006-02
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bremelanotide | Peptide | — | Intranasal |